BIOMAT Database Logo BIOMAT Database Logo

Plasma soluble fas and soluble fas ligand in chronic glomerulonephritis. 1998

H Sano, and K Asano, and S Minatoguchi, and J Hiraoka, and K Fujisawa, and K Nishigaki, and N Yasuda, and H Kumada, and M Takemura, and H Ohashi, and M Seishima, and T Fujiwara, and H Fujiwara
2nd Department of Internal Medicine, Gifu University School of Medicine, Gifu Prefectural Hospital, Gifu, Japan.

It has been reported that glomerular cells with apoptosis and positive Fas immunoreactivity are seen in proliferative glomerulonephritis (PGN). Fas induces apoptosis when it binds to Fas ligand (Fas-L) or soluble Fas-L (sFas-L). However, soluble Fas (sFas) blocks apoptosis by inhibiting binding between Fas and Fas-L or sFas-L. That is, Fas, Fas-L, and sFas-L are inducers of apoptosis, but sFas is an inhibitor of apoptosis. We studied the relationship between the plasma levels of sFas and sFas-L in 32 patients with various types of adult chronic glomerulonephritis. Patients with serum creatinine levels >1.5 mg/dl (132.6 micromol/l) were excluded. The plasma levels of sFas-L were within the normal limits in all patients. The plasma levels of sFas in the patients with minimal-change (n = 8) and membranous nephropathy (n = 7) were similar to the age- and sex-matched controls. However, the plasma sFas levels were significantly elevated in patients with mesangial PGN (n = 10) and membranoproliferative glomerulonephritis (n = 7)(3. 4 +/- 0.9 and 3.9 +/- 1.5 ng/ml, respectively) as compared with the age- and sex-matched controls (controls: 2.1 +/- 0.4 and 2.2 +/- 0.6 ng/ml, respectively). In PGN, according to increase of histological grade and decrease of creatinine clearance, the number of TUNEL-positive cells in glomeruli is decreased in spite of an increase of the Fas positivity, and plasma sFas is increased. The degree of proliferative change is determined by the balance between proliferation and apoptosis and/or necrosis. Therefore, increased plasma sFas in PGN may inhibit apoptosis in glomeruli and may be one of the progressing factors in PGN. Thus, we conclude that an increase in plasma sFas levels is important to the protection of apoptosis in PGN.

UI MeSH Term Description Entries
D008024 Ligands A molecule that binds to another molecule, used especially to refer to a small molecule that binds specifically to a larger molecule, e.g., an antigen binding to an antibody, a hormone or neurotransmitter binding to a receptor, or a substrate or allosteric effector binding to an enzyme. Ligands are also molecules that donate or accept a pair of electrons to form a coordinate covalent bond with the central metal atom of a coordination complex. (From Dorland, 27th ed) Ligand
D008297 Male Males
D008562 Membrane Glycoproteins Glycoproteins found on the membrane or surface of cells. Cell Surface Glycoproteins,Surface Glycoproteins,Cell Surface Glycoprotein,Membrane Glycoprotein,Surface Glycoprotein,Glycoprotein, Cell Surface,Glycoprotein, Membrane,Glycoprotein, Surface,Glycoproteins, Cell Surface,Glycoproteins, Membrane,Glycoproteins, Surface,Surface Glycoprotein, Cell,Surface Glycoproteins, Cell
D008657 Metabolic Clearance Rate Volume of biological fluid completely cleared of drug metabolites as measured in unit time. Elimination occurs as a result of metabolic processes in the kidney, liver, saliva, sweat, intestine, heart, brain, or other site. Total Body Clearance Rate,Clearance Rate, Metabolic,Clearance Rates, Metabolic,Metabolic Clearance Rates,Rate, Metabolic Clearance,Rates, Metabolic Clearance
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D002908 Chronic Disease Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2). Chronic Condition,Chronic Illness,Chronically Ill,Chronic Conditions,Chronic Diseases,Chronic Illnesses,Condition, Chronic,Disease, Chronic,Illness, Chronic
D003404 Creatinine Creatinine Sulfate Salt,Krebiozen,Salt, Creatinine Sulfate,Sulfate Salt, Creatinine
D005260 Female Females
D005921 Glomerulonephritis Inflammation of the renal glomeruli (KIDNEY GLOMERULUS) that can be classified by the type of glomerular injuries including antibody deposition, complement activation, cellular proliferation, and glomerulosclerosis. These structural and functional abnormalities usually lead to HEMATURIA; PROTEINURIA; HYPERTENSION; and RENAL INSUFFICIENCY. Bright Disease,Kidney Scarring,Glomerulonephritides,Scarring, Kidney
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

H Sano, and K Asano, and S Minatoguchi, and J Hiraoka, and K Fujisawa, and K Nishigaki, and N Yasuda, and H Kumada, and M Takemura, and H Ohashi, and M Seishima, and T Fujiwara, and H Fujiwara
Raised plasma soluble Fas and Fas-ligand in alcoholic liver disease.
June 1998, Lancet (London, England),
H Sano, and K Asano, and S Minatoguchi, and J Hiraoka, and K Fujisawa, and K Nishigaki, and N Yasuda, and H Kumada, and M Takemura, and H Ohashi, and M Seishima, and T Fujiwara, and H Fujiwara
Plasma-soluble Fas (APO-1, CD95) and soluble Fas ligand in immune thrombocytopenic purpura.
April 2000, European journal of haematology,
H Sano, and K Asano, and S Minatoguchi, and J Hiraoka, and K Fujisawa, and K Nishigaki, and N Yasuda, and H Kumada, and M Takemura, and H Ohashi, and M Seishima, and T Fujiwara, and H Fujiwara
[Clinical significances of serum soluble fas and soluble fas ligand in chronic hepatitis B].
December 2006, The Korean journal of hepatology,
H Sano, and K Asano, and S Minatoguchi, and J Hiraoka, and K Fujisawa, and K Nishigaki, and N Yasuda, and H Kumada, and M Takemura, and H Ohashi, and M Seishima, and T Fujiwara, and H Fujiwara
Serum soluble Fas (CD95) and Fas ligand profiles in chronic kidney failure.
October 2000, The Journal of laboratory and clinical medicine,
H Sano, and K Asano, and S Minatoguchi, and J Hiraoka, and K Fujisawa, and K Nishigaki, and N Yasuda, and H Kumada, and M Takemura, and H Ohashi, and M Seishima, and T Fujiwara, and H Fujiwara
Circulating levels of soluble Fas ligand and soluble Fas in patients with chronic obstructive pulmonary disease.
December 2000, Respiratory medicine,
H Sano, and K Asano, and S Minatoguchi, and J Hiraoka, and K Fujisawa, and K Nishigaki, and N Yasuda, and H Kumada, and M Takemura, and H Ohashi, and M Seishima, and T Fujiwara, and H Fujiwara
Soluble Fas antigen and soluble Fas ligand in early neonatal life.
December 2003, Early human development,
H Sano, and K Asano, and S Minatoguchi, and J Hiraoka, and K Fujisawa, and K Nishigaki, and N Yasuda, and H Kumada, and M Takemura, and H Ohashi, and M Seishima, and T Fujiwara, and H Fujiwara
Soluble fas antigen and soluble fas ligand in intrauterine growth restriction.
January 2010, Neonatology,
H Sano, and K Asano, and S Minatoguchi, and J Hiraoka, and K Fujisawa, and K Nishigaki, and N Yasuda, and H Kumada, and M Takemura, and H Ohashi, and M Seishima, and T Fujiwara, and H Fujiwara
Serum levels of soluble Fas ligand and soluble Fas receptor in patients with chronic congestive heart failure.
December 2002, Chinese medical sciences journal = Chung-kuo i hsueh k'o hsueh tsa chih,
H Sano, and K Asano, and S Minatoguchi, and J Hiraoka, and K Fujisawa, and K Nishigaki, and N Yasuda, and H Kumada, and M Takemura, and H Ohashi, and M Seishima, and T Fujiwara, and H Fujiwara
Clinical significance of serum soluble Fas, Fas ligand and fas in intrahepatic lymphocytes in chronic hepatitis C.
January 2008, Immunological investigations,
H Sano, and K Asano, and S Minatoguchi, and J Hiraoka, and K Fujisawa, and K Nishigaki, and N Yasuda, and H Kumada, and M Takemura, and H Ohashi, and M Seishima, and T Fujiwara, and H Fujiwara
Soluble Fas (APO-1, CD95) and soluble Fas ligand in rheumatic diseases.
June 1997, Arthritis and rheumatism,
Copied contents to your clipboard!